# Clinical Trials Data KRAS - Document 41

# Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01394120

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histologic diagnosis of pancreas adenocarcinoma\n\* Clinical stage IV\n\* Feasible patient for chemotherapy\n\* Availability of tumor tissue or possibility of a tumor biopsy to define therapeutic targets\n\* Informed written consent\n\nExclusion Criteria:\n\n\* Previous systemic treatment for advanced pancreas adenocarcinoma\n\* Contraindication to the administration of any of the drugs used in the study: capecitabine, 5Fluouracil, irinotecan, oxaliplatin, gemcitabine or erlotinib",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
The provided clinical trial information does not specify KRAS gene mutation status as either an inclusion or exclusion criterion for eligibility. Therefore, having a KRAS gene mutation would not automatically render a patient ineligible for the trial based on the provided criteria. However, eligibility would depend on other factors outlined, such as the requirement for having stage IV pancreas adenocarcinoma, an available tumor tissue sample, no previous systemic treatment for advanced pancreas adenocarcinoma, and not having contraindications to the specified drugs. It's important for interested patients to discuss their specific circumstances with the trial investigators or their healthcare provider to determine eligibility.